Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis
暂无分享,去创建一个
Ž. Reiner | G. Derosa | P. Maffioli | A. Sahebkar | L. E. Simental-Mendía | L. Simental-Mendía | L. Simental‐Mendía
[1] A. Sahebkar,et al. Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. , 2016, British journal of clinical pharmacology.
[2] C. Zoccali,et al. A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[3] A. Sahebkar,et al. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2015, Pharmacological research.
[4] J. Coombes,et al. Effects of atorvastatin on oxidative stress in chronic kidney disease , 2015, Nephrology.
[5] A. Sahebkar,et al. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. , 2015, Progress in lipid research.
[6] A. Sahebkar,et al. Association between statin use and plasma D-dimer levels , 2015, Thrombosis and Haemostasis.
[7] J. Mckenney,et al. Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials. , 2015, Journal of clinical lipidology.
[8] A. Tsubota,et al. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C , 2014, European journal of gastroenterology & hepatology.
[9] Y. Matsumoto,et al. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. , 2014, Biological & pharmaceutical bulletin.
[10] M. Matsuzaki,et al. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). , 2013, Cardiovascular therapeutics.
[11] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[12] H. Takagi,et al. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. , 2012, International journal of cardiology.
[13] B. Tomlinson,et al. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial , 2011, Scandinavian journal of rheumatology.
[14] J. Tomassini,et al. Long‐term efficacy and safety of ezetimibe/simvastatin coadministered with extended‐release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome , 2010, Diabetes, obesity & metabolism.
[15] S. Fujimori,et al. Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients , 2010, Nucleosides, nucleotides & nucleic acids.
[16] G. Gensini,et al. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. , 2010, International journal of cardiology.
[17] D. Moher,et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2009, PLoS medicine.
[18] A. Reunanen,et al. Hyperuricemia as a risk factor for cardiovascular mortality. , 2009, Acta medica Scandinavica. Supplementum.
[19] Yun-dai Chen,et al. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia , 2008, Heart and Vessels.
[20] D. Mikhailidis,et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. , 2005, Metabolism: clinical and experimental.
[21] L. Niskanen,et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. , 2004, Archives of internal medicine.
[22] M. Elisaf,et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] H. Milionis,et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. , 2004, American heart journal.
[24] J. Seeger,et al. Clinically relevant differences between the statins: implications for therapeutic selection. , 2001, The American journal of medicine.
[25] C. Stancu,et al. Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.
[26] Y. Moriwaki,et al. Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. , 2001, Metabolism: clinical and experimental.
[27] Alex J. Sutton,et al. Methods for Meta-Analysis in Medical Research , 2000 .
[28] H. Yamanaka,et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. , 2000, Journal of epidemiology.
[29] S Duval,et al. Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.
[30] M. Pahor,et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. , 1999, Hypertension.
[31] A. Palomäki,et al. Enhanced oxidizability of ubiquinol and α‐tocopherol during lovastatin treatment , 1997, FEBS letters.
[32] Y. Moriwaki,et al. Impaired lipoprotein metabolism in patients with primary gout--influence of alcohol intake and body weight. , 1994, British journal of rheumatology.
[33] L. Amorosa,et al. Fluvastatin with and without niacin for hypercholesterolemia. , 1994, The American journal of cardiology.
[34] F. Cappuccio,et al. Uric acid metabolism and tubular sodium handling. Results from a population-based study. , 1993, JAMA.
[35] A. Sahebkar,et al. Statin therapy and plasma cortisol concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2016, Pharmacological research.
[36] J. Wiliński,et al. Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients. , 2013, Przeglad lekarski.
[37] J. Higgins,et al. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .
[38] M. Dimopoulos,et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. , 2011, Atherosclerosis.
[39] C. Ballantyne,et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia , 2009 .
[40] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.
[41] Juan Carlos Espinosa,et al. Comprehensive Meta-Analysis , 2004 .
[42] A. Dyer,et al. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. , 1989, Journal of clinical epidemiology.